Article
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab.
JCO precision oncology - 1 Jun 2023
Lipsyc-Sharf Marla, Jain Esha, Collins Laura C, Rosenberg Shoshana M, Ruddy Kathryn J, Tamimi Rulla M, Schapira Lidia, Come Steven E, Peppercorn Jeffrey M, Borges Virginia F, Warner Ellen, Snow Craig, Krop Ian E, Kim Dewey, Weiss Jakob, Zanudo Jorge Gomez Tejeda, Partridge Ann H, Wagle Nikhil, Waks Adrienne G
Abstract excerpt
PURPOSE: Erb-B2 receptor tyrosine kinase 2 (ERBB2)-positive breast cancer (BC) is particularly common in young women. Genomic features of ERBB2-positive tumors before and after chemotherapy and trastuzumab (chemo + H) have not been described in young women and are important for guiding study of therapeutic resistance in this population. METHODS: From a large prospective cohort of women age 40 years or younger...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.